KRC-108

• Description:

  KRC-108, an aminopyridine, is an orally active multiple kinase inhibitor with IC50s of 80 nM, 23 nM, 3 nM, 70 nM, 30 nM, 39 nM for c-Met, c-Met M1250T, c-Met Y1230D, Ron, Flt3 and TrkA, respectively. KRC-108 induces cell cycle arrest, apoptotic cell death, and autophagy. KRC-108 exhibits anti-tumor activity in vivo in HT29 colorectal cancer, NCI-H441 lung cancer xenograft models in athymic BALB/c nu/nu mice[1].

• UNSPSC:

  12352005

• Target:

  Apoptosis; Autophagy; c-Met/HGFR; FLT3; Trk Receptor

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Autophagy; Neuronal Signaling; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/krc-108.html

• Smiles:

  NC1=NC=C(C=C1C2=NC3=CC=CC=C3O2)C4=CN(N=C4)C5CCNCC5

• Molecular Formula:

  C20H20N6O

• Molecular Weight:

  360.41

• References & Citations:

  [1]Sun-Young Han, et al. Evaluation of a multi-kinase inhibitor KRC-108 as an anti-tumor agent in vitro and in vivo. Invest New Drugs. 2012 Apr;30 (2) :518-23.|[2]Hyo Jeong Lee, et al. Characterization of KRC-108 as a TrkA Kinase Inhibitor with Anti-Tumor Effects. Biomol Ther (Seoul) . 2022 Jul 1;30 (4) :360-367.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  Met; TrkA

• CAS Number:

  [1146944-35-5]